Completed PHASE1 INTERVENTIONAL NCT01324843

Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects

Safety and Tolerability of the Derma Vax Clinical Intradermal Electroporation System in Healthy Subjects

Sponsor: National Institute on Aging (NIA)

Interventions Aveeno Daily Moist Derma Vax EMLA Cream Intradermal Electroporation McGill Pain Questionnaire Present Pain Intensity Skin Assessment Visual Analogue Scale

Updated 5 times since 2017 Last updated: Jun 30, 2017 Started: Jun 25, 2009 Primary completion: May 27, 2010 Completion: May 27, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Intradermal Electroporation, this trial is completed. The trial is conducted by National Institute on Aging (NIA) and has accumulated 5 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Aging (NIA)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States